top of page

35+ YEARS IN MEDICAL DEVICE | PHARMACEUTICAL | BIOTECHNOLOGY | DIAGNOSTICS

Insights and News Curated for Life Science Experts by Life Science Experts....

Go back to...

Executive Spotlights

Lesson’s Learned from Building out the Commercial Organization

SK Life Science breaks through Covid barriers to bring epilepsy drug to market

Lutronic’s Focus on Change during the Pandemic

From Big Pharma to Startup: What are the Challenges?

The View from Olympus: How This MedTech Leader Approached the Pandemic

DENTALEZ COO Heather Trombley on Reinvigorating the Company

Seqirus Exec on Vaccine Differentiation

Zimmer Biomet VP on Covering the Territory

How Teleflex Grew its Market Value 4x in 6 Years

Admedus COO David St. Denis on Courage, Commitment and Conversation

1 min read

Axonis Therapeutics Secures $115M Series A to Advance Neuromedicine Pipeline

Boston, MA, October 30, 2024 (PRNewswire) -- Axonis Therapeutics raised $115 million in Series A funding to advance AXN-027 for epilepsy and pain treatment. Axonis will advance its oral KCC2 pipeline to treat neurological conditions.

Read full article here.

Recent Posts

Celltex Therapeutics Welcomes Anita Perry as CEO

Houston, TX, November 5, 2024 (PRNewswire) -- Celltex Therapeutics appointed Anita Perry as CEO following the retirement of Co-Founder...

Alpha-9 Oncology Secures $175M Series C to Drive Radiopharmaceutical Innovation in Cancer Treatment

Boston, MA and Vancouver, Canada, October 23, 2024 (PRNewswire) -- Alpha-9 Oncology has raised $175 million in Series C funding to...

I-Mab Appoints Dr. Sean Fu as Permanent CEO to Lead Advancement of Cancer Immunotherapy Programs

Rockville, MD, November 6, 2024 (PRNewswire) -- I-Mab has named Dr. Sean Fu as its CEO to drive forward its cancer immunotherapy...

Komentarze

Life Science Headlines

Axonis Therapeutics Secures $115M Series A to Advance Neuromedicine Pipeline

Celltex Therapeutics Welcomes Anita Perry as CEO

Alpha-9 Oncology Secures $175M Series C to Drive Radiopharmaceutical Innovation in Cancer Treatment

I-Mab Appoints Dr. Sean Fu as Permanent CEO to Lead Advancement of Cancer Immunotherapy Programs

AbbVie Acquires Aliada Therapeutics for $1.4B to Expand Alzheimer's Research Portfolio

Terray Therapeutics Secures $120M in Series B Funding to Revolutionize Small Molecule Drug Development with Advanced AI

ViaNautis Bio Appoints Dr. Adi Hoess as CEO to Propel Growth in Genetic Therapies

AvenCell Therapeutics Secures $112M in Series B Funding to Advance Innovative Switchable CAR-T Cell Therapies

Mike Alvarez Appointed CEO of Glooko to Drive Growth Following $100 Million Series F Financing

Seaport Therapeutics Secures $225M in Oversubscribed Series B Financing to Propel Neuropsychiatric Drug Development

bottom of page